Professor Georgina Long is changing the lives of people with advanced melanoma, with new results from a world-first trial in Sydney.
The Keynote-029 trial, led by Professor Long at the Melanoma Institute of Australia, is being shown to shrink melanoma tumours significantly in 57 per cent of people participating in the trial.
With the trial treating people with advanced melanoma, the positive results for some are potentially life-saving.
In several cases, scans showed total eradication of tumours after three months of treatment.
The trial involves the world-first combination of two specific immunotherapy drugs.
The drugs – pembrolizumab (KeytrudaTM) and ipilimumab (YervoyTM) – boost the body’s immune system into controlling and killing cancer cells.
The results were presented in June at the American Society of Clinical Oncology’s Annual Meeting in Chicago, Illinois.
Georgina is Chair of melanoma medical oncology and translational research at University of Sydney and a clinical researcher at Melanoma Institute Australia.
She has been supported by the Cancer Institute NSW through the NSW Premier’s Award for Outstanding Cancer Research, winning in consecutive years.
In 2013 she won the Outstanding Cancer Research Fellow Award and in 2014 she won the Wildfire Award, both recognising her work and achievements in the advancements of melanoma treatments and survival.
For more information, visit the Melanoma Institute of Australia.
Beating skin cancer starts at prevention
Australia currently has the second highest rate of melanoma and skin cancer in the world behind only to New Zealand.
In 2012 it made up over 10 per cent of cancer cases in NSW, and accounted for over 500 deaths.
There are five easy ways everybody can reduce their risk of skin cancer throughout the whole year:
- protective clothing
Find out more about skin cancer prevention in NSW.